Maintenance therapy with continuous or switch strategy in advanced non-small cell lung cancer: A systematic review and meta-analysis

Chest

Volumn 140, Issue 1, 2011, Pages 117-126

  Zhang, Xinji ^a   Zang, Jiajie ^a   Xu, Jinfang ^a   Bai, Chong ^a   Qin, Yingyi ^a   Liu, Ke ^b   Wu, Cheng ^a   Wu, Meijing ^a   He, Qian ^a   Zhang, Shanshan ^c   Wei, Lixin ^c   He, Jia ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IMATINIB; LOMUSTINE; METHOTREXATE; MITOMYCIN; PEMETREXED; PLACEBO;

ANEMIA; ANOREXIA; CANCER RADIOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; FATIGUE; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCORING SYSTEM; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VOMITING;

EID: 79960414995     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.10-2745     Document Type: Review

References (36)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96.
2. Azzoli CG, Baker S Jr, Temin S, et al; American Society of Clinical Oncology. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2009;27(36): 6251-6266.
3. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27(8):1227-1234.
4. Leighl NB, Paz-Ares L, Douillard JY, et al. Randomized phase III study of matrix metalloproteinase inhibitor BMS- 275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol. 2005;23(12):2831-2839. (Pubitemid 46179474)
5. Williamson SK, Crowley JJ, Lara PN Jr, et al; Southwest Oncology Group Trial S0003. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced nonsmall- cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol. 2005;23(36):9097-9104.
6. National Comprehensive Cancer Network. Clinical practice guidelines in oncology for non-small cell lung cancer v.2. 2010. National Comprehensive Cancer Network Web site. http:// www.nccn.org/professionals/physician-gls/f- guidelines.asp. Accessed March 5, 2010.
7. Pérol M, Zalcman G, Monnet I, et al. Final results from the IFCT-GFPC 0502 phase III study: maintenance therapy in advanced NSCLC with either gemcitabine(G) or erlotinib (E) versus observation(O) after cisplatin-gemcitabine induction chemotherapy(CT), with predefined second-line treatment [abstract]. Ann Oncol. 2010;21(suppl 8):viii 124.
8. Cappuzzo F, Ciuleanu T, Stelmakh L, et al; SATURN investigators . Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebocontrolled phase 3 study. Lancet Oncol. 2010;11(6):521-529.
9. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374(9699):1432-1440.
10. Miller VA, Das A, Rossi M. A randomized, double-blind, placebo-controlled, phase IIIb trial(ATLAS) comparing bevacizumab(B) therapy with or without erlotinib(E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer(NSCLC) [abstract LBA8002]. J Clin Oncol. 2009; 27(suppl 1):18S.
11. Kabbinavar FF, Miller VA, Johnson BE, et al. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab(B) therapy with or without erlotinib(E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) [abstract 7526]. J Clin Oncol. 2010;28(suppl):15S.
12. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12. (Pubitemid 26120810)
13. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815-2834. (Pubitemid 28562978)
14. Higgins JPT, Green S(editors). Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions 5.0.1. The Cochrane Collaboration, 2011. http ://www.cochrane-handbook.org. Updated March, 2011. Accessed May 2010.
15. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560. (Pubitemid 37088507)
16. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326(7382):219. (Pubitemid 36143396)
17. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634. (Pubitemid 27387172)
18. Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008;26(15):2450-2456.
19. Hanna N, Neubauer M, Yiannoutsos C, et al; Hoosier Oncology Group; US Oncology. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol. 2008;26(35):5755-5760.
20. Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV nonsmall- cell lung cancer. J Clin Oncol. 2005;23(27):6674-6681. (Pubitemid 46190262)
21. Zarogoulidis K, Ziogas E, Dermitzakis G. The survival benefit of maintenance therapy of NSCLC patients responding to initial treatment: A randomized trial. Eur J Cancer. 1995; 31(suppl 6):S231-S232.
22. Westeel V, Quoix E, Moro-Sibilot D, et al; French Thoracic Oncology Collaborative Group(GCOT). Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2005;97(7): 499-506. (Pubitemid 40590431)
23. Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol. 2002; 20(5):1335-1343. (Pubitemid 34182817)
24. Belani CP, Barstis J, Perry MC, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol. 2003; 21(15):2933-2939. (Pubitemid 46621844)
25. Takeda K, Hida T, Sato T, et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol. 2010;28(5):753-760.
26. Johnson EA, Marks RS, Mandrekar SJ, et al. Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy(NCCTG 97-24-51). Lung Cancer. 2008;60(2):200-207. (Pubitemid 351609147)
27. Buccheri GF, Ferrigno D, Curcio A, Vola F, Rosso A. Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study. Cancer. 1989;63(3):428-432. (Pubitemid 19038453)
28. Brodowicz T, Krzakowski M, Zwitter M, et al; Central European Cooperative Oncology Group CECOG. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced nonsmall cell lung cancer: a phase III trial. Lung Cancer. 2006; 52(2):155-163.
29. Belani CP, Waterhouse DM, Ghazal H, et al. Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin(G-Cb) for patients with advanced non-small cell lung cancer(NSCLC) [abstract 7506]. J Clin Oncol. 2010;28(suppl):15S.
30. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced nonsmall- cell lung cancer. J Clin Oncol. 2009;27(4):591-598.
31. Surmont VF, Gaafar RM, Scagliotti GV, et al. A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib(G) in patients(pts) with advanced NSCLC, nonprogressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01/03) [abstract]. Ann Oncol. 2010; 21(suppl 8):viii 124.
32. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advancedstage non-small-cell lung cancer. J Clin Oncol. 2008;26(21): 3543-3551.
33. Ricciardi S, Tomao S, de Marinis F. Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer. 2009;10(1):28-35.
34. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2000;18(1):122-130. (Pubitemid 30036345)
35. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinumbased chemotherapy. J Clin Oncol. 2000;18(10):2095-2103. (Pubitemid 30324363)
36. Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol. 2009;27(20):3277-3283.